
Law Offices of Howard G. Smith Encourages SelectQuote, Inc. (SLQT) Investors To Inquire About Securities Fraud Class Action
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SELECTQUOTE, INC. (SLQT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On May 1, 2025, the U.S. Department of Justice ('DOJ') filed a False Claims Act complaint against SelectQuote, alleging, '[f]rom 2016 through at least 2021' SelectQuote received 'tens of millions of dollars' in 'illegal kickbacks' from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers 'unbiased coverage comparisons' when in fact it 'repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans.'
On this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025, on unusually heavy trading volume.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provided unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Contact Us To Participate or Learn More:
If you purchased SelectQuote securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Are Wall Street Analysts Bullish on Humana Stock?
Humana Inc. (HUM) is a leading U.S. health insurance company headquartered in Louisville, Kentucky, with a market cap of about $33.1 billion. Operating in the healthcare sector, specifically within the managed healthcare industry, Humana offers a broad portfolio of medical and specialty insurance products, with a strong focus on Medicare Advantage plans. The company serves millions of members nationwide through its Insurance and CenterWell segments, which encompass health services, pharmacy solutions, and primary care. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! The medicare giant's 2025 journey has been a steady cruise so far, with its shares up about 8.4% year-to-date (YTD) - enough to show strength - though still a step behind the S&P 500 Index's ($SPX) 9.6% gain. However, HUM stock shines in its own lane, easily outperforming the SPDR S&P Health Care Services ETF (XHS), which gained just 2.9% over the same period. But widen the lens to the past 52 weeks, and the picture shifts. HUM is down by 21.1%, not just lagging behind the SPX's 20.6% gains, but also XHS, which dipped by 1.6%. The stock has recently regained momentum following its mixed second-quarter report released on July 30, with adjusted EPS of $6.27, compared to the prior-year quarter value of $6.96, while revenue climbed to $32.4 billion. Investors rejoiced as the company raised its full-year EPS outlook to around $17 and forecasted revenue of at least $128 billion, driven by improved Medicare Advantage retention, stabilized medical costs, and continued growth in its CenterWell Pharmacy segment. While the broader healthcare sector has been weighed down by rising medical costs, regulatory pressures, and a pullback in medicare advantage expansion, Humana's operational improvements and upbeat guidance have boosted investor confidence, setting it apart from sector peers. For the current fiscal year, ending in December 2025, analysts expect HUM to report EPS growth of 4.8% YoY to $16.99, on a diluted basis. The company has a decent track record of beating Wall Street's estimates, topping consensus EPS estimates in three of the trailing four quarters. Among the 22 analysts covering HUM stock, the consensus rating is a 'Moderate Buy.' That's based on six 'Strong Buys,' two 'Moderate Buys,' and 14 'Hold' ratings. The current configuration has remained largely consistent over the past few months. Earlier this month, Raymond James doubled down on its bullish stance for HUM stock, keeping the 'Outperform' rating and $340 target after Q2 2025 results, and an upbeat outlook from management. The mean price target of $289.38 indicates a premium of 5.3% to HUM's current price, while the Street-high price target of $348 suggests an upside potential of 26.6%. On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
15 minutes ago
- Yahoo
Here's Legacy Ridge Capital Partners' Investment Thesis for Polaris (PII)
Legacy Ridge Capital Management released its 2025 mid-year letter recently. A copy of the same can be downloaded here. The partnership returned -1.7% gross and net of performance fees through June 2025. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second-quarter 2025 investor letter, Legacy Ridge Capital Management highlighted stocks such as Polaris Inc. (NYSE:PII). Polaris Inc. (NYSE: PII) is a manufacturer of powersports vehicles, operating through three segments: Off-Road, On-Road, and Marine. The one-month return of Polaris Inc. (NYSE:PII) was 17.86%, and its shares lost 31.01% of their value over the last 52 weeks. On August 12, 2025, Polaris Inc. (NYSE:PII) stock closed at $55.29 per share, with a market capitalization of $3.109 billion. Legacy Ridge Capital Management stated the following regarding Polaris Inc. (NYSE:PII) in its second quarter 2025 investor letter: "One of the new investments we made this year is in Polaris Inc. (NYSE:PII), a manufacturer of powersports vehicles, including: Side-by-sides, ATVs, snowmobiles (Off-Road Segment), motorcycles (On-Road Segment), and boats (Marine Segment). Side-by-sides—Rangers and Razors—look like mini-trucks and dune buggy type vehicles, respectively. A motorcyclist enjoying the open road on a sunny day. Polaris Inc. (NYSE:PII) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Polaris Inc. (NYSE:PII) at the end of the first quarter, which was 26 in the previous quarter. In Q2 2025, Polaris Inc.'s (NYSE:PII) sales declined 6%, due to the ongoing powersports industry downturn and increased promotions. While we acknowledge the potential of Polaris Inc. (NYSE:PII) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Polaris Inc. (NYSE:PII) and shared Artisan Mid Cap Value Fund's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
15 minutes ago
- Yahoo
Madison Square Garden Takes Hit From Concert Slowdown, Stock Falls
Madison Square Garden Entertainment (NYSE:MSGE) stock dropped after it reported its fiscal fourth-quarter 2025 results. The quarterly revenue declined by 17% year-on-year (Y/Y) to $154.14 million, beating the analyst consensus estimate of $152.24 million. Earnings loss per share of 57 cents missed the analyst consensus loss estimate of 49 from entertainment offerings decreased 17% Y/Y to $118.7 million, primarily due to lower event-related revenues and a decrease in revenues subject to the sharing of economics with Madison Square Garden Sports under the Arena License Agreements. Food, beverage, and merchandise revenues declined 24% Y/Y to $26.4 million. Event-related revenues decreased by $21.6 million due to lower concert revenues. View more earnings on MSGE In addition, the company reported an adjusted operating loss of $1.3 million, versus $13.1 million profit a year ago, primarily due to the decrease in revenues. As of June 30, cash and equivalents stood at $43.5 million. The company said it hosted nearly 6 million guests at more than 975 events, including concerts, special events, family shows, marquee sports, and the New York Knicks' regular season, playoff run, and the New York Rangers' regular season. It sold about 1.1 million tickets for 200 shows of the Christmas Spectacular, generating another year of record-setting revenue. The company also repurchased approximately $40 million of its Class A common stock during the year. Madison Square Garden Entertainment stock gained 13% year-to-date. Price Action: MSGE stock is trading lower by 3.03% to $39.00 premarket at last check Wednesday. Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Madison Square Garden Takes Hit From Concert Slowdown, Stock Falls originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.